Posted: 01 Aug 2017 06:22 PM PDT
By Anne K. Walsh & Andrew J. Hull –
The Department of Justice announced on July 24, 2017, that Celgene agreed, without admitting liability, to pay a total of $280 million to settle a qui tam case relating to two of its drug products, Thalomid® and Revlimid®. The qui tam complaint filed in the U.S. District Court for the Central District of California, alleged that Celgene promoted the use of these two drugs to treat cancer patients outside the scope of the FDA-approved uses for those drugs. In addition to allegations that the company promoted the drug for numerous uses that were off-label, the relator alleged that:
At the end of the day, the government receives a big payment, even though it did not intervene and litigate the matter. Winner, winner.
Mesothelioma | Answers to Common Questions
Hace 21 minutos